Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Deferred Revenue: 2017-2024

Historic Current Deferred Revenue for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $18.9 million.

  • Protagonist Therapeutics' Current Deferred Revenue fell 60.77% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 60.77%. This contributed to the annual value of $18.9 million for FY2024, which is 629600.00% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Current Deferred Revenue is $18.9 million, which was up 629,600.00% from $3,000 recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Current Deferred Revenue ranged from a high of $18.9 million in FY2024 and a low of $3,000 during FY2023.
  • In the last 3 years, Protagonist Therapeutics' Current Deferred Revenue had a median value of $69,000 in 2022 and averaged $6.3 million.
  • In the last 5 years, Protagonist Therapeutics' Current Deferred Revenue crashed by 95.69% in 2022 and then spiked by 629,600.00% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Current Deferred Revenue (Yearly) stood at $14.5 million in 2020, then slumped by 88.94% to $1.6 million in 2021, then crashed by 95.69% to $69,000 in 2022, then crashed by 95.65% to $3,000 in 2023, then soared by 629,600.00% to $18.9 million in 2024.